Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.39 |
| ▸ | CES1 | P23141 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.34 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.32 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.32 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.32 |
| ▸ | CHRNG | P07510 | 1/20 | 0.32 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | CHRND | Q07001 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24849873 | 0.71 | CES2 (0.42) | CES2CES1RAB9AMEN1KMT2A | |
| SCHEMBL16961724 | 0.70 | CES2 (0.48) | CES2CES1RAB9AMEN1KMT2A | |
| SCHEMBL24288735 | 0.68 | TP53 (0.34) | — | |
| SCHEMBL2126134 | 0.66 | CES2 (0.59) | CES2CES1RAB9AMEN1KMT2A | |
| SCHEMBL4790688 | 0.65 | CES2 (0.52) | CES2CES1RAB9AMEN1KMT2A | |
| SCHEMBL2096114 | 0.65 | CES2 (0.52) | CES2CES1RAB9AMEN1KMT2A | |
| SCHEMBL6921313 | 0.65 | CES2 (0.52) | CES2CES1RAB9AMEN1KMT2A | |
| SCHEMBL26708378 | 0.65 | LDHA (0.48) | RAB9A | |
| SCHEMBL6963321 | 0.63 | CES2 (0.54) | CES2CES1RAB9AMEN1KMT2A | |
| SCHEMBL16957209 | 0.62 | CES2 (0.44) | CES2CES1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10450286-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450286-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | CES2 54/4885CES1 37/4885RAB9A 2916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.